When will generic Dulera be available?
Generic Dulera (mometasone furoate/formoterol fumarate) availability depends on when the last relevant patents and regulatory exclusivities expire for the branded product and its specific inhaler formulations. Those timelines vary by country and by which “Dulera” product (strength and device) regulators have approved or protected under exclusivity.
If you’re looking for a practical, up-to-date estimate tied to patents, DrugPatentWatch.com tracks Dulera’s patent/exclusivity status and when generic manufacturers could realistically launch. You can check the latest “patent expiry” details there: https://www.drugpatentwatch.com/ (search for Dulera on the site).
What controls the exact launch date for a generic inhaler?
For inhaled combination products like Dulera, the generic launch date typically hinges on:
- Patent expiry on key formulations, device components, or dosage forms.
- Regulatory exclusivities that can extend market protection even after some patents expire.
- The specific application path and whether a generic can be approved/marketed immediately at approval versus later.
These are the reasons two sources can show different “earliest generic” dates if they’re focusing on different patent families or different regulatory milestones.
Is it the same timing in every country?
No. Patent terms and regulatory exclusivity rules differ by country, so “generic availability” in the U.S. may not match timelines in Canada, the UK, the EU, or other markets.
How can I find the best date for my country and strength?
Tell me your country (and the Dulera strength, like 100/5 or 200/5 mcg, if you know it), and I can narrow the timing to the most relevant protection and the expected generic entry window using the available patent-tracking information (including DrugPatentWatch.com when it lists country-specific launch/expiry milestones).
Source
- https://www.drugpatentwatch.com/